We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
Read MoreHide Full Article
Key Takeaways
Agenus launched the phase III BATTMAN study for BOT/BAL in refractory MSS colorectal cancer.
AGEN reported nearly 42% two-year survival and about 21-month median survival in studies.
Agenus expanded BOT/BAL access globally and strengthened manufacturing via Zydus collaboration.
Agenus’ (AGEN - Free Report) growth story is becoming increasingly tied to the progress of its lead immuno-oncology combination, botensilimab plus balstilimab (BOT/BAL), particularly in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). The company has recently advanced the program into late-stage development by initiating the global phase III BATTMAN study, marking an important milestone for its pipeline.
The late-stage study is evaluating BOT/BAL in patients with refractory MSS mCRC, a setting in which currently approved checkpoint inhibitors have historically shown limited benefit. This has made MSS colorectal cancer one of the more difficult markets for immunotherapy developers and an area of significant unmet medical need.
So far, BOT/BAL has generated encouraging survival data in heavily pretreated patients. According to Agenus, the regimen demonstrated nearly 42% two-year overall survival and a median overall survival of about 21 months in earlier-stage studies. The company believes these results could support future accelerated approval efforts in the United States and conditional approval pathways in Europe.
Beyond clinical development, Agenus is also expanding international access to the regimen through named-patient and reimbursed early-access programs in select markets, including France. The company also strengthened its manufacturing and liquidity position earlier this year through its collaboration with Zydus Lifesciences, which supports future BOT/BAL production readiness and commercialization efforts.
AGEN Faces Intense Competition in Target Markets
Agenus faces stiff competition from Big Pharma in its target markets.
The company competes with well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda and Bristol Myers’ (BMY - Free Report) Opdivo and Yervoy. These drugs have strong commercial positions across multiple cancer indications, making it difficult for smaller biotech companies to establish market share.
AGEN’s Price Performance, Valuation and Estimates
Shares of Agenus have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AGEN is currently trading at a discount to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 0.95 times forward 12-month sales, below the industry average of 1.96 times.
Image Source: Zacks Investment Research
Estimate revisions for Agenus’ 2026 and 2027 bottom line have been mixed over the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
Key Takeaways
Agenus’ (AGEN - Free Report) growth story is becoming increasingly tied to the progress of its lead immuno-oncology combination, botensilimab plus balstilimab (BOT/BAL), particularly in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). The company has recently advanced the program into late-stage development by initiating the global phase III BATTMAN study, marking an important milestone for its pipeline.
The late-stage study is evaluating BOT/BAL in patients with refractory MSS mCRC, a setting in which currently approved checkpoint inhibitors have historically shown limited benefit. This has made MSS colorectal cancer one of the more difficult markets for immunotherapy developers and an area of significant unmet medical need.
So far, BOT/BAL has generated encouraging survival data in heavily pretreated patients. According to Agenus, the regimen demonstrated nearly 42% two-year overall survival and a median overall survival of about 21 months in earlier-stage studies. The company believes these results could support future accelerated approval efforts in the United States and conditional approval pathways in Europe.
Beyond clinical development, Agenus is also expanding international access to the regimen through named-patient and reimbursed early-access programs in select markets, including France. The company also strengthened its manufacturing and liquidity position earlier this year through its collaboration with Zydus Lifesciences, which supports future BOT/BAL production readiness and commercialization efforts.
AGEN Faces Intense Competition in Target Markets
Agenus faces stiff competition from Big Pharma in its target markets.
The company competes with well-established immunotherapies such as Merck’s (MRK - Free Report) Keytruda and Bristol Myers’ (BMY - Free Report) Opdivo and Yervoy. These drugs have strong commercial positions across multiple cancer indications, making it difficult for smaller biotech companies to establish market share.
AGEN’s Price Performance, Valuation and Estimates
Shares of Agenus have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AGEN is currently trading at a discount to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 0.95 times forward 12-month sales, below the industry average of 1.96 times.
Image Source: Zacks Investment Research
Estimate revisions for Agenus’ 2026 and 2027 bottom line have been mixed over the past 30 days.
Image Source: Zacks Investment Research
Agenus currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.